19 research outputs found
āļāļēāļĢāđāļāđāļĒāļēāļĨāļēāļĄāļīāļ§āļđāļāļĩāļāđāļĢāļīāđāļĄāļāđāļāđāļāļāļēāļĢāļĢāļąāļāļĐāļēāđāļĢāļāđāļ§āļĢāļąāļŠāļāļąāļāļāļąāļāđāļŠāļāđāļĢāļ·āđāļāļĢāļąāļāļāļāļīāļāļāļĩ: āļāļēāļĢāļĻāļķāļāļĐāļēāļāļāļāļ§āļāļāļĢāļ°āļ§āļąāļāļīāļāļđāđāļāđāļ§āļĒāļĒāđāļāļāļŦāļĨāļąāļ Lamivudine as Initial Treatment for Chronic Hepatitis B Virus in a University Teaching Hospital: a Retrospective Patient Record Review Study
āļ§āļąāļāļāļļāļāļĢāļ°āļŠāļāļāđ: āđāļāļ·āđāļāļāļĢāļ°āđāļĄāļīāļāļāļĨāļĨāļąāļāļāđāļāļēāļāļāļĨāļīāļāļīāļ āđāļŦāļāļļāļāļēāļĢāļāđāđāļĄāđāļāļķāļāļāļĢāļ°āļŠāļāļāđāđāļĨāļ°āļĻāļķāļāļĐāļēāļĢāļđāļāđāļāļāļāļēāļĢāđāļāļīāđāļĄāļŦāļĢāļ·āļāđāļāļĨāļĩāđāļĒāļāļĒāļēāļ āļēāļĒāļŦāļĨāļąāļāļāļēāļĢāđāļāđāļĒāļēāļĨāļēāļĄāļīāļ§āļđāļāļĩāļāđāļāđāļāļāļąāļ§āđāļĢāļāđāļāļāļēāļĢāļĢāļąāļāļĐāļēāđāļĢāļāđāļ§āļĢāļąāļŠāļāļąāļāļāļąāļāđāļŠāļāđāļĢāļ·āđāļāļĢāļąāļāļāļāļīāļāļāļĩ āļ§āļīāļāļĩāļāļēāļĢāļĻāļķāļāļĐāļē: āđāļāđāļāļāļēāļĢāļĻāļķāļāļĐāļēāđāļāļīāļāļāļĢāļĢāļāļāļēāđāļāļāđāļāđāļāļāđāļāļĄāļđāļĨāļĒāđāļāļāļŦāļĨāļąāļāđāļāļāļđāđāļāđāļ§āļĒāđāļĢāļāđāļ§āļĢāļąāļŠāļāļąāļāļāļąāļāđāļŠāļāđāļĢāļ·āđāļāļĢāļąāļāļāļāļīāļāļāļĩāļāļĩāđāđāļĢāļīāđāļĄāļāđāļāļāļēāļĢāļĢāļąāļāļĐāļēāļāđāļ§āļĒāļĒāļēāļĨāļēāļĄāļīāļ§āļđāļāļĩāļ āļāļāļēāļ 150 āļĄāļīāļĨāļĨāļīāļāļĢāļąāļĄ āļ āđāļĢāļāļāļĒāļēāļāļēāļĨāļĄāļŦāļēāļĢāļēāļāļāļāļĢāđāļāļĩāļĒāļāđāļŦāļĄāđ āļ.āđāļāļĩāļĒāļāđāļŦāļĄāđ āļāļēāļāļ§āļ 98 āļāļ āļāļĩāđāđāļāđāļēāļĢāļąāļāļāļēāļĢāļĢāļąāļāļĐāļēāđāļāļāđāļ§āļāļ§āļąāļāļāļĩāđ 1 āļĄāļāļĢāļēāļāļĄ āļ.āļĻ.2548 - 31 āļāļąāļāļ§āļēāļāļĄ āļ.āļĻ. 2552 āļāļĨāļāļēāļĢāļĻāļķāļāļĐāļē: āļāļđāđāļāđāļ§āļĒāļāļēāļāļ§āļ 98 āļāļ āđāļāđāļāđāļāđāļāļāļđāđāļāđāļ§āļĒāļāļĨāļļāđāļĄ HBeAg positive 55 āļāļ (āļĢāđāļāļĒāļĨāļ° 56.1) āđāļĨāļ° HBeAg negative 43 āļāļ (āļĢāđāļāļĒāļĨāļ° 43.9) āđāļāļĒāļāļđāđāļāđāļ§āļĒāļāļĨāļļāđāļĄ HBeAg positive āļāļāļāļēāļĢāđāļāļīāļ seroconversion āļĢāđāļāļĒāļĨāļ° 16.4 āđāļĨāļ°āļĄāļĩāļĢāļ°āļāļąāļ HBV DNA āļāđāļēāļāļāļāļĢāļ§āļāđāļĄāđāļāļāļāđāļēāļāļ§āđāļēāļāļĨāļļāđāļĄ HBeAg negative (āļĢāđāļāļĒāļĨāļ° 18.2 āđāļĨāļ° āļĢāđāļāļĒāļĨāļ° 53.5) āđāļāđāļāļāļ§āđāļēāļĄāļĩāļĢāļ°āļāļąāļāļāļāļ alanine aminotransferase (ALT) āļāļĨāļąāļāļŠāļđāđāļāđāļēāļāļāļāļīāļŠāļđāļāļāļ§āđāļē (āļĢāđāļāļĒāļĨāļ° 76.4 āđāļĨāļ°āļĢāđāļāļĒāļĨāļ° 69.8) āļāļāļāļēāļĢāđāļāļīāļ virological breakthrough āđāļāļāļĨāļļāđāļĄ HBeAg positive āļĄāļēāļāļāļ§āđāļē HBeAg negative (āļĢāđāļāļĒāļĨāļ° 23.6 āđāļĨāļ° 18.6 ) āđāļĄāđāļāļāļāļēāļĢāļāļąāļāļāļķāļāđāļŦāļāļļāļāļēāļĢāļāđāđāļĄāđāļāļķāļāļāļĢāļ°āļŠāļāļāđāļāļĩāđāļāļāļāđāļāļĒāļĢāļ°āļŦāļ§āđāļēāļāļāļēāļĢāļĢāļąāļāļĐāļēāđāļāđāļāļāđāļŦāļāļļāļāļēāļĢāļāđāđāļĄāđāļāļķāļāļāļĢāļ°āļŠāļāļāđāļāļĩāđāļāļāļāđāļāļĒāđāļāđāļĄāļĩāļāļ§āļēāļĄāļĢāļļāļāđāļĢāļ āļāļ·āļ āļāļēāļĢāđāļāļīāļ hepatitis flares āļāļēāļāļ§āļ 6 āļĢāļēāļĒ (āļĢāđāļāļĒāļĨāļ° 6.1) āđāļĨāļ°āđāļāļīāļ substantial biochemical change āļāļēāļāļ§āļ 5 āļĢāļēāļĒ (āļĢāđāļāļĒāļĨāļ° 5.1) āđāļĄāđāļāļāļāļēāļĢāļŦāļĒāļļāļāļĒāļēāļŦāļĢāļ·āļāđāļāļĨāļĩāđāļĒāļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļēāļāļāļēāļĢāđāļāļīāļāđāļŦāļāļļāļāļēāļĢāļāđāđāļĄāđāļāļķāļāļāļĢāļ°āļŠāļāļāđāļāļĩāđāļĢāļļāļāđāļĢāļ āđāļāļāļēāļĢāļĻāļķāļāļĐāļēāļāļĩāđāļāļāļāļēāļĢāđāļāļīāđāļĄāļĒāļēāđāļĨāļ°āđāļāļĨāļĩāđāļĒāļāļĒāļēāđāļāļāļđāđāļāđāļ§āļĒāļāļąāđāļāļŦāļĄāļāļĢāđāļāļĒāļĨāļ° 58.2 āđāļĨāļ°āļĢāđāļāļĒāļĨāļ° 1.0 āļāļēāļĄāļĨāļēāļāļąāļ āđāļāļĒāļŠāđāļ§āļāđāļŦāļāđāđāļāđāļāļāļđāđāļāđāļ§āļĒāđāļāļāļĨāļļāđāļĄ HBeAg positive āđāļĨāļ°āļāļāļŠāļąāļāļŠāđāļ§āļāļāļēāļĢāđāļāļīāđāļĄāļĒāļēāļāļĩāđāļāđāļāđāļ§āļĩāļĒāļĢāđāļĄāļēāļāļāļ§āđāļēāļāļ°āļāļĩāđāļāđāļ§āļĩāļĒāļĢāđāļāļķāđāļāđāļāđāļāđāļāļāļēāļĄāļāđāļāļāļēāļŦāļāļāļāļēāļĢāđāļāđāļĒāļēāļāļĩāđāļāđāļāđāļ§āļĩāļĒāļĢāđāļāļĩāđāļĢāļ°āļāļļāđāļ§āđāđāļāļāļąāļāļāļĩāļĒāļēāļŦāļĨāļąāļāđāļŦāđāļāļāļēāļāļī āļŠāļĢāļļāļ: āļāļēāļĢāđāļāđāļĒāļēāļĨāļēāļĄāļīāļ§āļđāļāļĩāļāđāļāļāļāļēāļ 150 āļĄāļīāļĨāļĨāļīāļāļĢāļąāļĄāđāļāļ·āđāļāđāļĢāļīāđāļĄāļāđāļāļāļēāļĢāļĢāļąāļāļĐāļēāđāļĢāļāđāļ§āļĢāļąāļŠāļāļąāļāļāļąāļāđāļŠāļāđāļĢāļ·āđāļāļĢāļąāļāļāļāļīāļāļāļĩ āļŠāļēāļĄāļēāļĢāļāļĨāļāļĢāļ°āļāļąāļāļāļāļ HBV DNA āļāđāļēāļāļāļāļĢāļ§āļāđāļĄāđāļāļ āđāļĨāļ° ALT āļāļĨāļąāļāļŠāļđāđāļāđāļēāļāļāļāļī āđāļĄāđāļ§āđāļēāļĄāļĩāļāļđāđāļāđāļ§āļĒāļāļēāļāļ§āļāļāđāļāļĒāđāļāļīāļ HBe seroconversion āđāļĨāļ°āļāđāļāļāļĄāļĩāļāļēāļĢāđāļāļīāđāļĄāļĒāļēāļĢāđāļāļĒāļĨāļ° 58.2 āļāļĨāļāļēāļĢāļĻāļķāļāļĐāļēāļŠāļ°āļāđāļāļāļāļēāļĢāđāļāđāļĒāļēāļāļēāļĢāļāļđāđāļĨāļāļāđāļāđāļāļģāļŠāļģāļāļąāļ: āđāļ§āļĢāļąāļŠāļāļąāļāļāļąāļāđāļŠāļāđāļĢāļ·āđāļāļĢāļąāļāļāļāļīāļāļāļĩ, āļĨāļēāļĄāļīāļ§āļđāļāļĩāļ, āļāļĨāļĨāļąāļāļāđāļāļēāļāļāļĨāļīāļāļīāļObjective: To evaluate clinical outcomes, adverse events and patterns of antiviral therapy from adding or changing medications during initial treatment with lamivudine for chronic hepatitis B (CHB) virus. Method: This retrospective descriptive study involved 98 patients with chronic hepatitis B who were treated with 150 mg lamivudine tablets at Maharaj Nakorn Chiang Mai Hospital from January 1st, 2005 to December 31st, 2009. Results: The 98 patients were divided into groups as 55 (56.1%) patients with HBeAg positive before the treatment, and 43 (43.9%) HBeAg negative. Patients with HBeAg positive had HBe seroconversion at 16.4% with HBV DNA below detection level and lower than HBeAg negative patients (18.2% and 53.5%); however, alanine aminotransferase (ALT) normalization was higher (76.4% and 69.8%). Virological breakthrough in HBeAg positive patients was higher than HBeAg negative patients (23.6% and 18.6%). Most common adverse events were not recorded during treatment but serious adverse events, hepatitis flares and substantial biochemical change were found in six (6.1%) and five patients (5.1%), respectively. No patients discontinued or changed their treatment as a result of serious adverse events. Adding and changing medication was carried out in 58.2% and 1.0% of patients respectively, who were mostly HBeAg positive. Patients added with tenofovir during lamivudine treatment were higher than those adding adefovir, which followed the terms of tenofovir as recorded in the National List of Essential Medicines. Conclusion: Our findings showed that use of lamivudine 150 mg as initial treatment for chronic hepatics B virus could achieve undetectable levels and ALT normalization, although a small number of patients had HBe seroconversion and 58.2% added other antivirals. The results reflects real-life practice.Keywords: chronic hepatitis B, lamivudine, clinical outcome
Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study.
Evidence of a role of vitamin D in the immune system is increasing. Low serum vitamin D is associated with increased hepatitis B virus replication. Genome-wide association study (GWAS) data has revealed a number of the single nucleotide polymorphisms (SNPs) within the vitamin D synthetic pathway that affect vitamin D functions. We aimed to determine the association between SNPs in the vitamin D gene cascade and response to pegylated interferon (PegIFN) therapy in hepatitis B e-antigen (HBeAg)-positive patients. One hundred and eleven patients treated for 48 weeks with PegIFN-alfa 2a at 13 hospitals were retrospectively evaluated. Thirteen SNPs derived from vitamin D cascade-related genes, including DHCR7 (rs12785878), CYP27B1 (rs10877012), CYP2R1 (rs2060793, rs12794714), GC (rs4588, rs7041, rs222020, rs2282679), and VDR (FokI, BsmI, Tru9I, ApaI, TaqI), were genotyped. Thirty-one patients (27.9%) seroconverted to HBeAg after 24 weeks of treatment. Multivariate analysis found pretreatment qHBsAg 2 times the upper limit of normal (OR = 3.83, 95% CI: 1.31-11.22, P = 0.014) predicted sustained HBeAg seroconversion after completion of PegIFN treatment. HBV DNA during study period tended to be lower with the rs12794714 CYP2R1 TT than the non-TT genotype. The rs12794714 CYP2R1 polymorphism may be a useful pretreatment factor predictive of sustained HBeAg seroconversion after PegIFN therapy. This study provides evidence that not only vitamin D level but also genetic variation of CYP2R1 in the vitamin D cascade influences host immune response in chronic HBV infection
Survival based on liver decompensation severity.
By overall, log rank tests showed survival difference between groups, p<0.001. Log rank test results between AD vs. ACLF groups, ACLF grade 1 vs. ACLF grade 2, and ACLF grade 2 vs. ACLF grade 3 were p<0.001, p = 0.002*, and p<0.001**, respectively.</p
Diagnostic performance of each prognostic score in predicting short-term mortality in ACLF patients.
a. 1-Month mortality prediction value. b. 3-Month mortality prediction value.</p